Development and Optimization of ivermectin-lipid nanocapsules intend for oral administration

GABRIELA ULLIO GAMBOA; SANTIAGO PALMA; JEAN PIERRE BENOIT; MARIANA BALLENT; CARLOS LANUSSE; ADRIAN LIFSCHITZ; DANIEL ALLEMANDI

Córdoba

Congreso; 3ª Reunión Internacional de Ciencias Farmacéuticas ? RICIFA 2014.; 2014

UNC y UNR

LNCs have emerged as very promissory alternative as drug delivery system. These carriers will both increase the solubility and stability of drugs which is critical for pharmaceutical systems intended for parenteral administration (1).They are also able to reduce toxicity and modify its pharmacokinetic parameters by prolonging circulation time and improving its tissue distribution. Besides, nanoparticles have the potential to promote increased drug internalization by phagocyte cells of the reticulo-endocytosis system, which are reservoirs of intracellular parasites or co-localized in the infection site. This fact would lead to increased efficacy in peripheral infection (2). IVM is a broad-spectrum antihelmintic agent used in human and veterinary medicine. The high lipophilicity of this molecule accounts for a wide tissue distribution and long residence time in plasma. The observed erratic bioavailability could be a consequence of the pharmaceutical dosage form (3). The LNC platform has been studied for the delivery of numerous compounds. However, Novel formulation strategies such as nanoparticulate systems have not been intensively explored in the veterinary field yet. The aim of this work was the development of LNC containing IVM and the evaluation of the kinetic behaviour as well as tissue distribution.